Meet Jesper Kjerulff, Chief operations officer and Global project lead
With a wealth of experience in pharmaceutical development at prominent drug companies, Jesper Kjerulff is a seasoned expert who has been at the forefront of every aspect, stage, and facet of the drug development process. His international background spans the EU, the US, China, and Japan, covering regulatory approvals, in-licensing, contract negotiations, governance structures within major drug development partnerships, and the leadership of large, global, cross-functional project teams.
"I have a deep understanding of what it takes to bring a drug from concept to market, including the potential pitfalls. I believe this knowledge is of substantial value to PharmNovo," says Jesper Kjernulff.
As Chief operating officer and Project lead for PN6047, Jesper oversees the entire project. His primary focus is creating value, strategically managing risks and front-loading activities that will be valuable in the long run.
Before joining PharmNovo, Jesper Kjerulff held influential positions at Lundbeck, where he spearheaded numerous global projects. One of his accomplishments was overseeing the successful development of the antidepressant drug Brintellix®/Trintellix®, which seamlessly progressed from pre-clinical development to global registration and launch, transforming patients' lives worldwide. Jesper envisions a similar trajectory for PN6047.
"I hope and believe our drug candidate will revolutionise the treatment of neuropathic pain, set new standards, and help millions of people who suffer.".
While the realisation of this vision may be years away, Jesper has meticulously charted a roadmap. In the short term, over the next 2–3 years, PharmNovo aims to demonstrate PN6047's efficacy in reducing neuropathic pain. In the medium term, spanning 5–8 years, he believes PharmNovo, likely in collaboration with a major pharmaceutical partner, will illustrate that PN6047 fundamentally differs from conventional opioids.
"Our goal is to overcome the stigma surrounding opioids and gain approval for PN6047's use in treating neuropathic pain."
When asked about the key factors behind his belief in PN6047's success, Jesper emphasises the critical role of the team. The team, he asserts, cannot compensate for an ineffective drug, but given a potent drug, the team's expertise and dedication will be the driving force of success.
"PharmNovo's crowning achievement is assembling a team of 14 individuals, each bringing a unique blend of experience, dedication, responsibility, enthusiasm, collaboration, and competence".
As PharmNovo works to relieve the suffering of individuals with chronic pain, Jesper Kjerulff plays a vital role within the company. His objective is clear:
"I aim to make a difference. Not for personal recognition but to improve the world in a responsible way. My goal is to drive progress, solve problems, and create meaningful results".
Meet Jesper Kjerulff, Chief operations officer and Global project lead
With a wealth of experience in pharmaceutical development at prominent drug companies, Jesper Kjerulff is a seasoned expert who has been at the forefront of every aspect, stage, and facet of the drug development process. His international background spans the EU, the US, China, and Japan, covering regulatory approvals, in-licensing, contract negotiations, governance structures within major drug development partnerships, and the leadership of large, global, cross-functional project teams.
"I have a deep understanding of what it takes to bring a drug from concept to market, including the potential pitfalls. I believe this knowledge is of substantial value to PharmNovo," says Jesper Kjernulff.
As Chief operating officer and Project lead for PN6047, Jesper oversees the entire project. His primary focus is creating value, strategically managing risks and front-loading activities that will be valuable in the long run.
Before joining PharmNovo, Jesper Kjerulff held influential positions at Lundbeck, where he spearheaded numerous global projects. One of his accomplishments was overseeing the successful development of the antidepressant drug Brintellix®/Trintellix®, which seamlessly progressed from pre-clinical development to global registration and launch, transforming patients' lives worldwide. Jesper envisions a similar trajectory for PN6047.
"I hope and believe our drug candidate will revolutionise the treatment of neuropathic pain, set new standards, and help millions of people who suffer.".
While the realisation of this vision may be years away, Jesper has meticulously charted a roadmap. In the short term, over the next 2–3 years, PharmNovo aims to demonstrate PN6047's efficacy in reducing neuropathic pain. In the medium term, spanning 5–8 years, he believes PharmNovo, likely in collaboration with a major pharmaceutical partner, will illustrate that PN6047 fundamentally differs from conventional opioids.
"Our goal is to overcome the stigma surrounding opioids and gain approval for PN6047's use in treating neuropathic pain."
When asked about the key factors behind his belief in PN6047's success, Jesper emphasises the critical role of the team. The team, he asserts, cannot compensate for an ineffective drug, but given a potent drug, the team's expertise and dedication will be the driving force of success.
"PharmNovo's crowning achievement is assembling a team of 14 individuals, each bringing a unique blend of experience, dedication, responsibility, enthusiasm, collaboration, and competence".
As PharmNovo works to relieve the suffering of individuals with chronic pain, Jesper Kjerulff plays a vital role within the company. His objective is clear:
"I aim to make a difference. Not for personal recognition but to improve the world in a responsible way. My goal is to drive progress, solve problems, and create meaningful results".
Latest news
View all
Positive final Phase I results
The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.
Read more
Meet Bengt von Mentzer, founder and Chief scientific advisor
Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.
Read more
NIDA funds studies
The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.
Read more
Meet Olof Breuer, MD, Clinical pharmacology lead
Olof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.
Read more